Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00416702 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
A Phase 1 study of Hepatic Insufficiency, sponsored by Novartis.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00416702 is a Phase 1 study of Hepatic Insufficiency that has completed, run by Novartis. The registered enrollment target is 32 participants, below the 38-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (16% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00416702, a Phase 1 study of Hepatic Insufficiency, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the safety and pharmacokinetic effects of indacaterol in subjects with impaired liver function in comparison with healthy subjects
Conditions Studied
Interventions
- DRUG QAB149
Study Locations (1)
New Jersey
- Novartis Investigative Site - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00416702
The ClinicalTrials.gov registry entry for NCT00416702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 38-participant average among 14 other Hepatic Insufficiency trials with a reported enrollment target (16% lower). The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which QAB149 is the first listed.
NCT00416702 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT00416702 about?
NCT00416702 is a clinical study titled "Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function". This study is designed to evaluate the safety and pharmacokinetic effects of indacaterol in subjects with impaired liver function in comparison with healthy subjects
What is the current status of trial NCT00416702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2006-11. Estimated completion is 2008-03.
What conditions does trial NCT00416702 study?
This clinical trial studies the following conditions: Hepatic Insufficiency.
What interventions are being tested in trial NCT00416702?
The interventions under investigation include: QAB149 (DRUG).
Who is sponsoring clinical trial NCT00416702?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00416702 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
RECRUITING · Phase 1
-
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
RECRUITING · Phase 1
-
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
COMPLETED · Phase 1
-
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
COMPLETED · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.